• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioTime

Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018

March 13, 2018 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office. Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: abbott, alucentmedical, Anika Therapeutics Inc., Baxter, BioTime, Brainstorm Cell Therapeutics, Kala Pharmaceuticals, medherant, milestonescientific, pertinaxpharma, smith&nephew, West Pharmaceutical Services

BioTime lands $2m for dry-AMD therapy

August 14, 2017 By Sarah Faulkner

BioTime

BioTime Inc. (NYSE:BTX) said today that its subsidiary, Cell Cure Neurosciences, has landed a $2 million grant from the Israel Innovation Authority for the development of its dry-AMD therapy, OpRegen. The Alameda, Calif.-based company’s OpRegen is an investigational therapy that delivers retinal pigment epithelial cells into the subretinal space to replace lost RPE cells. “This new […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: BioTime

Medtech stories we missed: Feb. 10, 2017

February 10, 2017 By Danielle Kirsh

From Glytec partnering to beat diabetes to Biolase, Gramercy Extremity Orthopedics and more getting FDA clearances, here are 7 recent medtech stories we missed this week, but were still worth mentioning. 1. BioTime proposes public offering of common stock Clinical-stage biotechnology company BioTech is intending to offer common stock shares in an underwritten public offering. BioTime focuses […]

Filed Under: Business/Financial News, Diabetes, Food & Drug Administration (FDA) Tagged With: Biolase, BioTime, Geneva health Solutions, Glytec, Gramercy Extremity Orthopedics, Lombard, Nioness

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS